Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing
Biotechnology and Bioengineering · 2023-09 · 120 (9) · 2601-2621
DOI: 10.1002/bit.28412 ↗At a glance
Übersichtsarbeit in Biotechnology and Bioengineering, 2023-05. Written by Qiang Fu and 3 co-authors. Institution: Department of Biomedical Engineering and Biotechnology, The University of Massachusetts Lowell, Lowell, Massachusetts, USA. Major MEDLINE topics: Dependovirus, Genetic Vectors. Cited 85 times so far (Crossref); 186 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Gene therapy is a promising therapeutic approach for genetic and acquired diseases nowadays. Among DNA delivery vectors, recombinant adeno‐associated virus (rAAV) is one of the most effective and safest vectors used in commercial drugs and clinical trials. However, the current yield of rAAV biomanufacturing lags behind the necessary dosages for clinical and commercial use, which embodies a concentrated reflection of low productivity of rAAV from host cells, difficult scalability of the rAAV‐producing bioprocess, and high levels of impurities materialized during production. Those issues directly impact the price of gene therapy medicine in the market, limiting most patients’ access to gene therapy. In this context, the current practices and several critical challenges associated with rAAV gene therapy bioprocesses are reviewed, followed by a discussion of recent advances in rAAV‐mediated gene therapy and other therapeutic biological fields that could improve biomanufacturing if these advances are integrated effectively into the current systems. This review aims to provide the current state‐of‐the‐art technology and perspectives to enhance the productivity of rAAV while reducing impurities during production of rAAV.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Biomedical Engineering and Biotechnology, The University of Massachusetts Lowell, Lowell, Massachusetts, USA.
- Department of Chemical Engineering, The University of Massachusetts Lowell, Lowell, Massachusetts, USA.
- Department of Pharmaceutical Sciences, The University of Massachusetts Lowell, Lowell, Massachusetts, USA.
ORCID profiles: Seongkyu Yoon
Cite
APA
Fu, Q., Polanco, A., Lee, Y. S., & Yoon, S. (2023). Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing. Biotechnology and Bioengineering, 120(9), 2601-2621. https://doi.org/10.1002/bit.28412
Vancouver
Fu Q, Polanco A, Lee YS, Yoon S. Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing. Biotechnology and Bioengineering. 2023;120(9):2601-2621. doi:10.1002/bit.28412
BibTeX
@article{Fu2023,
author = {Fu, Qiang and Polanco, Ashli and Lee, Yong Suk and Yoon, Seongkyu},
title = {Critical challenges and advances in recombinant adeno‐associated virus (rAAV) biomanufacturing},
journal = {Biotechnology and Bioengineering},
year = {2023},
volume = {120},
number = {9},
pages = {2601--2621},
doi = {10.1002/bit.28412}
}
EUVIMED